CoMind develops non-invasive brain monitoring hardware and AI analytics for use in clinical settings including intensive care units, surgical theatres, and emergency departments. Founded in 2018 and based in London, the company combines photonics technology with advanced artificial intelligence to measure neurophysiological parameters at the bedside without invasive procedures.
The company's flagship product, CoMind One, provides real-time insight into cerebral perfusion, autoregulation, and intracranial pressure through non-invasive measurement. CoVision, its AI-powered analytics platform, delivers predictive clinical insights designed to enhance patient safety and improve healthcare outcomes.
CoMind operates at the intersection of neurotechnology, photonics, and clinical medicine. The technical approach centres on making previously inaccessible brain signals measurable at the bedside, combining hardware innovation with algorithmic analysis to support clinical decision-making in critical care environments.
